Back to top
more

GENPREX (GNPX)

(Delayed Data from NSDQ)

$2.21 USD

2.21
23,047

+0.09 (4.25%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $2.15 -0.06 (-2.71%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GNPX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

GENPREX [GNPX]

Reports for Purchase

Showing records 1 - 20 ( 36 total )

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 2

03/25/2024

Company Report

Pages: 52

Improving Survival in Lung Cancer; Initiating Coverage at Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 100.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 3

02/06/2024

Company Report

Pages: 5

Neutral Rated 1:40 Reverse Split, Market Cap Now $10M, Is a Raise Next?

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 4

01/05/2024

Company Report

Pages: 5

Neutral Rated Business Update but - Fails to Mention Reverse Split ATM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 5

12/20/2023

Company Report

Pages: 5

Neutral Rated A Reverse Split and an ATM? Makes No Cents

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 6

12/15/2023

Company Report

Pages: 5

Is an ATM the Answer? Drip, Drip, Drip In the Prior Quarter (3Q) the Company Spent $7.7M with $11.7M Remaining So They Have to Do Something

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 7

11/17/2023

Company Report

Pages: 5

Neutral Rated Reports 3rd Quarter - Spends $7.7M, $11.7M Remains

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 8

10/05/2023

Company Report

Pages: 5

Neutral Rated Genprex to present data on the use of REQORSA

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 9

08/22/2023

Company Report

Pages: 5

Lowering to Neutral Reports Second Quarter Results: Spent $8M, $10M in Cash, raises $7.5M, but is it Enough?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 10

07/19/2023

Company Report

Pages: 5

Genprex signs exclusive license agreement for additional diabetes technology-BUY Rated, $3.0 PT

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 11

07/06/2023

Company Report

Pages: 5

The patent covers the use of Genprex''s lead drug candidate, REQORSA Immunogene Therapy, in combination with PD1 antibodies through 2037.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 12

06/27/2023

Company Report

Pages: 5

The company has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 13

05/30/2023

Company Report

Pages: 5

Oncology Program Update

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 14

03/02/2023

Company Report

Pages: 5

BUY - Raises $4M, but

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 15

02/23/2023

Company Report

Pages: 12

Buy Rated The Diabetes Abstract is Out - Works in Non-Human Primates

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 16

02/04/2023

Company Report

Pages: 2

Research terminates coverage-due to termination of termination of research services by Genprex.

Provider: Diamond Equity Research LLC

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 17

01/30/2023

Company Report

Pages: 24

Buy Rating & $3.0 Target An Emerging Gene Therapy Platform in Oncology & Diabetes

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 35.00

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 18

12/01/2022

Company Report

Pages: 6

Third Quarter Financial Result Update and REQORSA Patent Granted

Provider: Diamond Equity Research LLC

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 19

12/01/2022

Company Report

Pages: 6

Third Quarter Financial Result Update and REQORSA Patent Granted

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 12.50

Research Provided by a Third Party

Company: GENPREX

Industry: Medical - Biomedical and Genetics

Record: 20

08/17/2022

Company Report

Pages: 5

Acclaim 1/2 Trial Progress Supported by Strong Balance Sheet

Provider: Diamond Equity Research LLC

Analyst: DIAMOND H

Price: 5.00

Research Provided by a Third Party